Xu, J., Song, F., Lyu, H., Kobayashi, M., Zhang, B., Zhao, Z., Hou, Y., Wang, X., Luan, Y., Jia, B., Stasiak, L., Wong, J. H., Wang, Q., Jin, Q., Jin, Q., Fu, Y., Yang, H., Hardison, R. C., Dovat, S., … Yue, F. (2022). Subtype-specific 3D genome alteration in acute myeloid leukaemia. Nature, 611(7935), 387–398. https://doi.org/10.1038/s41586-022-05365-x

Jung, S., Armstrong, E., Wei, A. Z., Ye, F., Lee, A., Carlino, M. S., Sullivan, R. J., Carvajal, R. D., Shoushtari, A. N., & Johnson, D. B. (2022). Clinical and genomic correlates of imatinib response in melanomas with KIT alterations. British Journal of Cancer, 127(9), 1726–1732. https://doi.org/10.1038/s41416-022-01942-z

Li, Q., Lesseur, C., Neugut, A. I., Santella, R. M., Parada, H., Teitelbaum, S., & Chen, J. (2022). The associations of healthy lifestyle index with breast cancer incidence and mortality in a population-based study. Breast Cancer, 29(6), 957–966. https://doi.org/10.1007/s12282-022-01374-w

Sharma, M., Lathers, D., Johnson, M., Luke, J., Puzanov, I., Curti, B., Chen, C., El-Khoueiry, A., Henick, B., Callahan, M., Sznol, M., Patel, S., Wilson, D., Ricker, M., Cao, L., Jayaraman, P., Che, J., Peng, L., Feltquate, D., … Tolcher, A. (2022). 772 A phase 1/2 dose escalation/expansion study evaluating the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of E-602, a bi-sialidase fusion protein, in advanced cancer (GLIMMER-01). Regular and Young Investigator Award Abstracts, A803–A803. https://doi.org/10.1136/jitc-2022-sitc2022.0772

Baljevic, M., Gasparetto, C., Schiller, G. J., Tuchman, S. A., Callander, N. S., Lentzsch, S., Monge, J., Kotb, R., Bahlis, N. J., White, D., Chen, C. I., Sutherland, H. J., Madan, S., LeBlanc, R., Sebag, M., Venner, C. P., Bensinger, W. I., Biran, N., DeCastro, A., … Lipe, B. (2022). Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment. EJHaem, 3(4), 1270–1276. Portico. https://doi.org/10.1002/jha2.572

Castano, V. G., Spotnitz, M., Waldman, G. J., Joiner, E. F., Choi, H., Ostropolets, A., Natarajan, K., McKhann, G. M., Ottman, R., Neugut, A. I., Hripcsak, G., & Youngerman, B. E. (2022). Identification of patients with drug‐resistant epilepsy in electronic medical record data using the Observational Medical Outcomes Partnership Common Data Model. Epilepsia, 63(11), 2981–2993. Portico. https://doi.org/10.1111/epi.17409

Parada, H., Sahrai, L., Wolff, M. S., Santella, R. M., Chen, J., Neugut, A. I., & Teitelbaum, S. L. (2022). Urinary parabens and breast cancer risk: Modification by LINE‐1 and LUMA global DNA methylation, and associations with breast cancer defined by tumor promoter methylation status. Molecular Carcinogenesis, 61(11), 1002–1015. Portico. https://doi.org/10.1002/mc.23456

Murphy, C. G., Goldstein, J. M., Besharati, S., Kobsa, S., Salvatore, M. M., Rosenzweig, E. B., Ingham, M., Del Portillo, A., Takeda, K., Chandra, S., & Furfaro, D. (2022). A 52-Year-Old Man With Chest Pain and Dyspnea. CHEST, 162(5), e259–e264. https://doi.org/10.1016/j.chest.2022.05.020

Sykes, M. (2022). Developing pig-to-human organ transplants. Science, 378(6616), 135–136. https://doi.org/10.1126/science.abo7935

Doshi, S. D., Lichtenstein, M. R. L., Beauchemin, M. P., Raghunathan, R., Lee, S., Law, C., Accordino, M. K., Elkin, E. B., Wright, J. D., & Hershman, D. L. (2022). Factors Associated With Patients Not Receiving Oral Anticancer Drugs. JAMA Network Open, 5(10), e2236380. https://doi.org/10.1001/jamanetworkopen.2022.36380

Filliol, A., Saito, Y., Nair, A., Dapito, D. H., Yu, L.-X., Ravichandra, A., Bhattacharjee, S., Affo, S., Fujiwara, N., Su, H., Sun, Q., Savage, T. M., Wilson-Kanamori, J. R., Caviglia, J. M., Chin, L., Chen, D., Wang, X., Caruso, S., Kang, J. K., … Schwabe, R. F. (2022). Opposing roles of hepatic stellate cell subpopulations in hepatocarcinogenesis. Nature, 610(7931), 356–365. https://doi.org/10.1038/s41586-022-05289-6

Mishkin, A. D., Cheung, S. G., Hoffman, A., Leimbach, E. J., Dosovitz, S., & Mapara, M. (2022). High incidence of suicidal ideation in a series of patients with sickle cell disease after hematopoietic stem cell transplantation. Blood Advances, 6(19), 5542–5545. https://doi.org/10.1182/bloodadvances.2021006752

Savage, K. J., Horwitz, S. M., Advani, R., Christensen, J. H., Domingo-Domenech, E., Rossi, G., Morschhauser, F., Alpdogan, O., Suh, C., Tobinai, K., Shustov, A., Trneny, M., Yuen, S., Zinzani, P. L., Trümper, L., Ilidge, T., O’Connor, O. A., Pro, B., Miao, H., … Iyer, S. (2022). Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Advances, 6(19), 5550–5555. https://doi.org/10.1182/bloodadvances.2020003971

Ramsey, S. D., Bansal, A., Sullivan, S. D., Lyman, G. H., Barlow, W. E., Arnold, K. B., Watabayashi, K., Bell-Brown, A., Kreizenbeck, K., Le-Lindqwister, N. A., Dul, C. L., Brown-Glaberman, U. A., Behrens, R. J., Vogel, V., Alluri, N., & Hershman, D. L. (2022). Effects of a Guideline-Informed Clinical Decision Support System Intervention to Improve Colony-Stimulating Factor Prescribing. JAMA Network Open, 5(10), e2238191. https://doi.org/10.1001/jamanetworkopen.2022.38191

Li, Y., Goldberg, E. M., Chen, X., Xu, X., McGuire, J. T., Leuzzi, G., Karagiannis, D., Tate, T., Farhangdoost, N., Horth, C., Dai, E., Li, Z., Zhang, Z., Izar, B., Que, J., Ciccia, A., Majewski, J., Yoon, A. J., Ailles, L., … Lu, C. (2022). Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas. Molecular Cell, 82(20), 3901-3918.e7. https://doi.org/10.1016/j.molcel.2022.09.007

Mapanga, W., Norris, S. A., Craig, A., Pumpalova, Y., Ayeni, O. A., Chen, W. C., Jacobson, J. S., Neugut, A. I., Muchengeti, M., Pentz, A., Doherty, S., Minkowitz, S., Haffejee, M., Rebbeck, T., & Joffe, M. (2022). Prevalence of multimorbidity in men of African descent with and without prostate cancer in Soweto, South Africa. PLOS ONE, 17(10), e0276050. https://doi.org/10.1371/journal.pone.0276050

Pratz, K. W., Cherry, M., Podoltsev, N. A., Altman, J. K., Perl, A. E., Cooper, B. W., Jurcic, J. G., Lin, T. L., Schiller, G. J., Wu, R., Hill, J. E., Gill, S. C., James, A., Rich, E. S., Hasabou, N., & Levis, M. J. (2022). AML-256 A Phase 1 Study of Gilteritinib in Combination With Induction and Consolidation Chemotherapy in Patients With Newly Diagnosed Acute Myeloid Leukemia: Final Study Results. Clinical Lymphoma Myeloma and Leukemia, 22, S230. https://doi.org/10.1016/s2152-2650(22)01255-1

Wu, A., Xiao, Q. Y., McWatt, S., Utomo, R., Talis, A., Saraci, K., Brassett, C., Sagoo, M. G., Wingate, R., Chien, C.-L., Traxler, H., Waschke, J., Vielmuth, F., Yamada, Y., Sakurai, T., Zeroual, M., Olsen, J., El-Batti, S., Viranta-Kovanen, S., … Noël, G. P. J. C. (2022). The Anatomy Course During COVID-19: The Impact of Cadaver-Based Learning on the Initiation of Reflection on Death. Medical Science Educator, 32(5), 1033–1044. https://doi.org/10.1007/s40670-022-01609-7

Yeaton, A., Cayanan, G., Loghavi, S., Dolgalev, I., Leddin, E. M., Loo, C. E., Torabifard, H., Nicolet, D., Wang, J., Corrigan, K., Paraskevopoulou, V., Starczynowski, D. T., Wang, E., Abdel-Wahab, O., Viny, A. D., Stone, R. M., Byrd, J. C., Guryanova, O. A., Kohli, R. M., … Guillamot, M. (2022). The Impact of Inflammation-Induced Tumor Plasticity during Myeloid Transformation. Cancer Discovery, 12(10), 2392–2413. https://doi.org/10.1158/2159-8290.cd-21-1146

Masuda, I., Yamaki, Y., Detroja, R., Tagore, S., Moore, H., Maharjan, S., Nakano, Y., Christian, T., Matsubara, R., Lowe, T. M., Frenkel-Morgenstern, M., & Hou, Y.-M. (2022). tRNA methylation resolves codon usage bias at the limit of cell viability. Cell Reports, 41(4), 111539. https://doi.org/10.1016/j.celrep.2022.111539

Contento, I., Paul, R., Marin-Chollom, A. M., Ogden Gaffney, A., Sepulveda, J., Dominguez, N., Gray, H., Haase, A. M., Hershman, D. L., Koch, P., & Greenlee, H. (2022). Developing a Diet and Physical Activity Intervention for Hispanic/Latina Breast Cancer Survivors. Cancer Control, 29. https://doi.org/10.1177/10732748221133987

Zonder, J. A., Richter, J., Bumma, N., Brayer, J., Hoffman, J. E., Bensinger, W. I., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., Cronier, D., Houvras, Y., Lorenc, K. R., Kroog, G. S., Dhodapkar, M. V., Lentzsch, S., Cooper, D., & Jagannath, S. (2022). MM-087 Early, Deep, and Durable Responses, and Low Rates of Cytokine Release Syndrome With REGN5458, a BCMAxCD3 Bispecific Antibody, in a Phase 1/2 First-In-Human Study in Patients With Relapsed/Refractory Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia, 22, S406–S407. https://doi.org/10.1016/s2152-2650(22)01591-9

Bäcker, H. C., Galle, S. E., Lentzsch, S., Freibott, C. E., Shoap, S., Strauch, R. J., & Rosenwasser, M. P. (2021). Flexor tenosynovectomy in carpal tunnel syndrome as a screening tool for early diagnosis of amyloidosis. Irish Journal of Medical Science (1971 -), 191(5), 2427–2430. https://doi.org/10.1007/s11845-021-02832-8

Chen, L. N., & Carvajal, R. D. (2022). Tebentafusp for the treatment of HLA-A*02:01–positive adult patients with unresectable or metastatic uveal melanoma. Expert Review of Anticancer Therapy, 22(10), 1017–1027. https://doi.org/10.1080/14737140.2022.2124971

Chakraborty, R., Bhutani, D., & Lentzsch, S. (2022). How do we manage t(11;14) plasma cell disorders with venetoclax? British Journal of Haematology, 199(1), 31–39. Portico. https://doi.org/10.1111/bjh.18243

Tolu, S. S., & Van Doren, L. (2022). Acute and chronic pain management in patients with sickle cell disease in the modern era: a comprehensive review. Transfusion and Apheresis Science, 61(5), 103533. https://doi.org/10.1016/j.transci.2022.103533

Crew, K. D., Bhatkhande, G., Silverman, T., Amenta, J., Jones, T., McGuinness, J. E., Mata, J., Guzman, A., He, T., Dimond, J., Tsai, W.-Y., & Kukafka, R. (2022). Patient and Provider Web-Based Decision Support for Breast Cancer Chemoprevention: A Randomized Controlled Trial. Cancer Prevention Research, 15(10), 689–700. https://doi.org/10.1158/1940-6207.capr-22-0013

Ford, M., Jin, Z., Orlando, E., Lipsky, A., Sawas, A., Pro, B., & Amengual, J. (2022). ABCL-542 Prevalence and Characterization of EBV-Negative Post-Transplant Lymphoproliferative Disorder. Clinical Lymphoma Myeloma and Leukemia, 22, S382–S383. https://doi.org/10.1016/s2152-2650(22)01546-4

Wu, A., & De Wit, H. (2022). The Liberal Model in Internationalization of Medical Education — an Opportunity to Reduce Healthcare Nationalism. Medical Science Educator, 32(5), 1235–1236. https://doi.org/10.1007/s40670-022-01623-9

Zhou, Y., Yang, Y., Guo, L., Qian, J., Ge, J., Sinner, D., Ding, H., Califano, A., & Cardoso, W. V. (2022). Airway basal cells show regionally distinct potential to undergo metaplastic differentiation. ELife, 11. CLOCKSS. https://doi.org/10.7554/elife.80083

Khan, S., Patel, S. P., Shoushtari, A. N., Ambrosini, G., Cremers, S., Lee, S., Franks, L., Singh-Kandah, S., Hernandez, S., Sender, N., Vuolo, K., Nesson, A., Mundi, P., Izar, B., Schwartz, G. K., & Carvajal, R. D. (2022). Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.975643

Hsu, E. J., Mendel, J. T., Ward, K. A., El-Ashmawy, M., Lee, M., Choy, H., Westover, K. D., Vo, D. T., Timmerman, R. D., Sher, D. J., & Iyengar, P. (2022). T Stage and Pretreatment Standardized Uptake Values Predict Tumor Recurrence With 5-Fraction SABR in Early-Stage Non-Small Cell Lung Cancer. Advances in Radiation Oncology, 7(5), 100995. https://doi.org/10.1016/j.adro.2022.100995

Huang, H., Fang, Y., Jiang, M., Zhang, Y., Biermann, J., Melms, J. C., Danielsson, J. A., Yang, Y., Qiang, L., Liu, J., Zhou, Y., Wang, M., Hu, Z., Wang, T. C., Saqi, A., Sun, J., Matsumoto, I., Cardoso, W. V., Emala, C. W., … Que, J. (2022). Contribution of Trp63CreERT2-labeled cells to alveolar regeneration is independent of tuft cells. ELife, 11. CLOCKSS. https://doi.org/10.7554/elife.78217

Tergas, A. I., Prigerson, H. G., Shen, M. J., Dinicu, A. I., Neugut, A. I., Wright, J. D., Hershman, D. L., & Maciejewski, P. K. (2022). Association between immigrant status and advanced cancer patients’ location and quality of death. Cancer, 128(18), 3352–3359. Portico. https://doi.org/10.1002/cncr.34385

Cogan, J. C., Accordino, M. K., Beauchemin, M. P., Spivack, J. H., Ulene, S. R., Elkin, E. B., Melamed, A., Taback, B., Wright, J. D., & Hershman, D. L. (2022). Efficacy of a password‐protected, pill‐dispensing device with mail return capacity to enhance disposal of unused opioids after cancer surgery. Cancer, 128(18), 3392–3399. Portico. https://doi.org/10.1002/cncr.34384

Cuker, A., Tseng, E. K., Schünemann, H. J., Angchaisuksiri, P., Blair, C., Dane, K., DeSancho, M. T., Diuguid, D., Griffin, D. O., Kahn, S. R., Klok, F. A., Lee, A. I., Neumann, I., Pai, A., Righini, M., Sanfilippo, K. M., Siegal, D. M., Skara, M., Terrell, D. R., … Nieuwlaat, R. (2022). American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis for patients with COVID-19: March 2022 update on the use of anticoagulation in critically ill patients. Blood Advances, 6(17), 4975–4982. https://doi.org/10.1182/bloodadvances.2022007940

Cuker, A., Tseng, E. K., Nieuwlaat, R., Angchaisuksiri, P., Blair, C., Dane, K., DeSancho, M. T., Diuguid, D., Griffin, D. O., Kahn, S. R., Klok, F. A., Lee, A. I., Neumann, I., Pai, A., Righini, M., Sanfilippo, K. M., Siegal, D. M., Skara, M., Terrell, D. R., … Schünemann, H. J. (2022). American Society of Hematology living guidelines on the use of anticoagulation for thromboprophylaxis in patients with COVID-19: January 2022 update on the use of therapeutic-intensity anticoagulation in acutely ill patients. Blood Advances, 6(17), 4915–4923. https://doi.org/10.1182/bloodadvances.2022007561

Kim, M. S., Naidoo, D., Hazra, U., Quiver, M. H., Chen, W. C., Simonti, C. N., Kachambwa, P., Harlemon, M., Agalliu, I., Baichoo, S., Fernandez, P., Hsing, A. W., Jalloh, M., Gueye, S. M., Niang, L., Diop, H., Ndoye, M., Snyper, N. Y., Adusei, B., … Lachance, J. (2022). Testing the generalizability of ancestry-specific polygenic risk scores to predict prostate cancer in sub-Saharan Africa. Genome Biology, 23(1). https://doi.org/10.1186/s13059-022-02766-z

Wei, A. Z., Uriel, M., Porcu, A., Manos, M. P., Mercurio, A. C., Caplan, M. M., Hulse, L., Seedor, R. S., Holovatska, M., Francis, J., Khan, S. A., McDonnell, D. E., Bogomolny, D., Sato, T., Marr, B. P., Haq, R., Orloff, M., Shoushtari, A., & Carvajal, R. D. (2022). Characterizing metastatic uveal melanoma patients who develop symptomatic brain metastases. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.961517

Wagner, M. J., Hennessy, C., Beeghly, A., French, B., Shah, D. P., Croessmann, S., Vilar-Compte, D., Ruiz-Garcia, E., Ingham, M., Schwartz, G. K., Painter, C. A., Chugh, R., Fecher, L., Park, C., Zamulko, O., Trent, J. C., Subbiah, V., Khaki, A. R., Tachiki, L., … Davis, E. J. (2022). Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort Study. Cancers, 14(17), 4334. https://doi.org/10.3390/cancers14174334

Berlin, A. (2022). Close Encounters of the First Kind: An Interdisciplinary Ethics of Care Approach Mitigates Moral Injury and Family Division in the Midst of Covid-19. Journal of Pain and Symptom Management, 64(3), e159–e164. https://doi.org/10.1016/j.jpainsymman.2021.03.028

Prebet, T., Goldberg, A. D., Jurcic, J. G., Khaled, S., Dail, M., Feng, Y., Green, C., Li, C., Ma, C., Medeiros, B. C., Yan, M., & Grunwald, M. R. (2022). A phase 1b study of atezolizumab in combination with guadecitabine for the treatment of acute myeloid leukemia. Leukemia & Lymphoma, 63(9), 2180–2188. https://doi.org/10.1080/10428194.2022.2057484

Yap, T. A., Moore, K. N., Patel, M., Henick, B. S., Do, D., Iheanacho, A., Zhang, H., Roche, M., Newberry, K., Hsieh, A., & Juric, D. (2022). 491TiP A first-in-human phase I/II study of BLU-222, a potent, selective CDK2 inhibitor in patients with CCNE1-amplified or CDK4/6 inhibitor-resistant advanced solid tumors. Annals of Oncology, 33, S765. https://doi.org/10.1016/j.annonc.2022.07.619

Sato, T., Ikeguchi, A. P., Nathan, P., Carvajal, R. D., Shoushtari, A. N., Gajewski, T. F., Hassel, J. C., Rioth, M., Leyvraz, S., Daniels, G. A., Hernandez-Aya, L., Johnson, D. B., Kim, K., Piulats Rodriguez, J. M., Cowey, C. L., Lockwood, S., Collins, L., Karakuzu, O., Sacco, J. J., & Butler, M. O. (2022). 843P Long-term survivors on tebentafusp in phase II trial of previously treated patients with metastatic uveal melanoma. Annals of Oncology, 33, S934–S935. https://doi.org/10.1016/j.annonc.2022.07.969

Ingram, M. A., Lauren, B. N., Pumpalova, Y., Park, J., Lim, F., Bates, S. E., Kastrinos, F., Manji, G. A., Kong, C. Y., & Hur, C. (2022). Cost‐effectiveness of neoadjuvant FOLFIRINOX versus gemcitabine plus nab‐paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports, 5(9). Portico. https://doi.org/10.1002/cnr2.1565

Cherston, C., Yoh, K., Huang, Y., Melamed, A., Gamble, C. R., Prabhu, V. S., Li, Y., Hershman, D. L., & Wright, J. D. (2022). Relative importance of individual insurance status and hospital payer mix on survival for women with cervical cancer. Gynecologic Oncology, 166(3), 552–560. https://doi.org/10.1016/j.ygyno.2022.06.023

Fu, J., Wang, Z., Martinez, M., Jiao, W., Frangaj, K., Jones, R., Guo, X. V., Zhang, Y., Kuo, W.-I., Obradovic, A., Ma, W., Rogers, K., Kato, T., Shen, Y., & Sykes, M. (2022). 425.3: Single-Cell Immune Profiling of Human Intestinal Allografts Reveals Differential Phenotypes of Alloreactive T-Cell Clones in Quiescent vs Chronically Rejecting Allografts. Transplantation, 106(9S), S485–S485. https://doi.org/10.1097/01.tp.0000888048.23424.42

Laise, P., Bosker, G., Califano, A., & Alvarez, M. J. (2022). A Patient‐to‐Model‐to‐Patient (PMP) Cancer Drug Discovery Protocol for Identifying and Validating Therapeutic Agents Targeting Tumor Regulatory Architecture. Current Protocols, 2(9). Portico. https://doi.org/10.1002/cpz1.544

Johnson, M. L., Rodon, J., Aljumaily, R., Villalona-Calero, M., Borazanci, E., Pishvaian, M., Turk, A., Carvajal, R. D., Mantia, C., Giaccone, G., Mounir, Z., Patel, A., Maurer, M., Neilan, C., Rajendran, D., Ganesan, U., Hinkle, J., & Tolcher, A. W. (2022). 492TiP A phase I study of synthetic lethal, IDE397 (MAT2A inhibitor) as a monotherapy and in combination with chemotherapy in advanced solid tumors harboring MTAP deletion. Annals of Oncology, 33, S766–S767. https://doi.org/10.1016/j.annonc.2022.07.620

Vikas, P., Korde, L. A., Somerfield, M. R., & Hershman, D. L. (2022). Use of Immune Checkpoint Inhibitors in the Treatment of High-Risk, Early-Stage Triple-Negative Breast Cancer: ASCO Guideline Rapid Recommendation Update Q and A. JCO Oncology Practice, 18(9), 649–651. https://doi.org/10.1200/op.22.00284